10X Genomics Inc expected to post a loss of 40 cents a share - Earnings Preview

10x Genomics

02/08/2023 03:05

* 10X Genomics Inc  TXG.OQ   TXG.O  is expected to show a
rise in
quarterly revenue when it reports  results on August 3. 
    * The Pleasanton California-based  company is expected to
report 
a 22.1% increase in revenue to $139.959 million from $114.61
million a year ago, according to the mean estimate from 10
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for 10X Genomics Inc is
for a
loss of 40 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 3
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for 10X
Genomics Inc
is $65​, above​ its last closing price of $62.25. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.35       -0.37      -0.44     Missed  -17.7
 Dec. 31 2023  -0.30       -0.31      -0.15     Beat    51.9
 Sep. 30 2022  -0.47       -0.46      -0.37     Beat    20.3​
 Jun. 30 2022  -0.40       -0.39      -0.57     Missed  -46.9
 ​​Mar.        -0.33       -0.31      -0.38     Missed  -21.5
 31 2022                                                
 Dec. 31 2021  -0.11       -0.09      -0.16     Missed  -85.2​
 Sep. 30 2021  -0.19       -0.20      -0.15     Beat    25.9
 Jun. 30 2021  -0.20       -0.26      -0.10     Beat    61.6
 This summary was machine generated August 2 at 02:04 GMT.  All
figures in US dollars  unless otherwise stated